Toggle menu


Start date:
November 2015
End date:
February 2015
Co-ordinated by:
NHS Lothian
Main trial site:

Diagnostic yield of an ambulatory patch monitor in Emergency Department syncope patients unexplained after Emergency Department evaluation – a pilot study (PATCH-ED)

EMERGE are excited to announce the PATCH-ED study – aiming to recruit 100 patients, PATCH-ED will involve an ambulatory patch monitor being applied to monitor heart beats for 14 days in eligible patients who present with an episode of syncope that remains unexplained after full ED assessment. A patch report will be provided by iRhythm Technologies, Inc. San Francisco, CA enabling any arrhythmias to be identified and informing appropriate follow-up.


Study Aims: PATCH-ED aims to investigate the diagnostic yield, prevalence of events captured on patch monitor, patient satisfaction of patch monitor, patch compliance and influence on subsequent treatment in ED syncope patients.


Study endpoints

Primary: Diagnostic yield of the ambulatory patch monitor for significant symptomatic arrhythmia at 90-day follow-up versus standard care strategies.

Sponsor: This study is sponsored by NHS Lothian.


Funding: Chest, Heart and Stroke Scotland

Setting: This is a single centre study being carried out in a teaching hospital ED, RIE.

Study Population: Patients presenting with an episode of syncope who after full ED assessment have no cause of syncope identified.


Eligibility Criteria

Inclusion criteria:

  • Patient presents within 6 hours of episode of syncope
  • Patient >16 years old
  • Syncope episode remains unexplained after ED assessment
  • Able to provide written informed consent

Syncope will be defined as a transient loss of consciousness (TLOC) with inability to maintain postural tone and immediate complete spontaneous recovery without medical intervention (to preexisting mental status and neurologic function)

Exclusion criteria:

  • Obvious underlying cause after ED assessment,
  • Alcohol or illicit drugs
  • Epileptic seizure (seizure activity with a >15 min witness reported post-ictal phase)
  • Stroke ⁄ transient ischemic attack
  • Head trauma
  • Hypoglycemia
  • No consent i.e. patient lacking capacity
  • Previous recruitment into the study
  • Patient in custody or prison

Obvious underlying causes will be defined as:

  • Clinical history of vasovagal syncope i.e. pre-syncope symptoms and low-risk patient according to current ESC guidelines
  • Arrhythmia on ED ECG thought to have caused syncope
  • Arrhythmia on pre-hospital ECG causing syncope
  • Pulmonary embolism diagnosed on CTPA (or equivalent e.g. symptoms of PE plus positive leg USS/VQ/echo)
  • Postural hypotension (postural drop >20 mmHg in ED with symptoms during test and suggestive history)
  • Myocardial Infarction


Chief Investigator:

Dr Matthew Reed

Research Team:

Kirsty Simpson, Research Nurse

Chief Investigator

Dr Matt Reed

Consultant and NRS Career Research Fellow in Emergency Medicine

Research Team

Allan MacRaild

Senior Research Nurse

Emma Ward

Research Administrator

Caroline Blackstock

AMU Senior Research Nurse

Megan McGrath

Senior Research Nurse

Related news

Exciting new trial: SNAP40

Exciting new trial: SNAP40

10 Apr 2017 | Megan McGrath

EMERGE will soon begin recruitment to the new SNAP40 trial which will compare the new SNAP40 device with standard monitoring devices in the Emergency Department.

Read more
The Beats That My Heart Skipped

The Beats That My Heart Skipped

23 Jan 2017 | Allan MacRaild

Heartbeats provide the rhythm of life. Interruptions to this rhythm are more likely to lead to a loss of consciousness than just a loss of spark. Rob Hannigan (pictured with Senior Research Nurse Allan MacRaild) took part in the PATCH-ED trial in 2016 following a number of unexplained blackouts. The results of his PATCH highlighted some dangerous arrhythmias including 24 seconds when his heart stopped beating entirely. Six months after his participation in the PATCH-ED trial, Rob met up with Allan to share his experiences.

Read more

More EMERGE Trials

1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.

Read more

RAMPP trial

RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more


Identification of Novel Psychoactive Substances (IONA)

The study with PP100-01 in combination with NAC is designed to determine safety and tolerability of PP100-01 when co-administered with NAC as compared to the 12-hr NAC treatment regime for patients that come to the hospital after an overdose of paracetamol/acetaminophen.

Read more

The POP Trial

A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose